Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A .2018 .Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 10(6) : 394-424.
Xue C,Dong H,Chen Y,Lu X,Zheng S,Cui H .2022 .Neoadjuvant Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. J Coll Physicians Surg Pak, 06(6) : 779-788.
Jiao J,Li WW,Shang YH,Li XF,Jiao M. .2023 .Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function. Pak J Med Sci, 10(2) : 6365-408.
Ma G,Chen W .2019 .Effect of Docetaxel Combined with Cisplatin Preoperative Neoadjuvant Chemotherapy for Stage III NSCLC. J Coll Physicians Surg Pak, 12(12) : 1230-1231.
Xian-Jun F,Xiu-Guang Q,Li Z,Hui F,Wan-Ling W,Dong L .2014 .ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy. Pak J Med Sci, 10(3) : 488-492.
Langen DAJ,Johnson ML,Mazieres J,Dingemans AMC,Mountzios G,Pless M .2023 .Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. , 6736(23) : 00221-0.
Bottger F,Radonic T,Bahce I,Monkhorst K,Piersma SR,Pham TV . .Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer. Mol Oncol, 10 : 13555.
Liu B,Wang Y,Tian S,Hertzanu Y,Zhao X,Li Y .2020 .Salvage treatment of NSCLC recurrence after first-line chemotherapy failure: Iodine-125 seed brachytherapy or microwave ablation? Thorac Cancer. , 10(3) : 13320-7714.
Saltos AN,Creelan BC,Tanvetyanon T,Chiappori AA,Antonia SJ,Shafique MR .2023 .A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer, 10 : 107313.
.2022 .Health Commission Of The People's Republic Of China N. National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version). Chin J Cancer Res, 03(3) : 9604-206.
. .US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. , : 50.
Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sargent D,Ford R .2008 .New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 10(2) : 228-247.
Wang HY,Chu JF,Zhao Y,Tang H,Wang LL,Zhou MQ .2020 .A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. Cancer Manag Res, 10 : 3827-3834.
He Z,Yang X,Ma T,Yang Q,Zhang C,Chen Y .2022 .Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as ifrst-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced nonsquamous non-small cell lung cancer in China: a multicenter, single-arm trial. Transl Lung Cancer Res, 10(8) : 1657-1666.
Li SH,Li YW,Li YJ,Liu LB,Zhang Q,Lu D .2023 .A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors. Int J Gen Med, 10 : 4485-4498.
Saharinen P,Eklund L,Pulkki K,Bono P,Alitalo K. VEGF .2011 .and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 17(7) : 347-362.
Hicklin DJ,Ellis LM .2005 .Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23(5) : 1011-1027.
Xu Y,Huang Z,Lu H,Yu X,Li Y,Li W .2019 .Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer, 10(8) : 640-646.
Zhao Y,Wan B,Zhang T,Xu Y,Liu H,Lv T .2019 .Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis. Transl Lung Cancer Res, 10(6) : 829-837.
Liu Y,Li HM,Wang R.,Effectiveness R. .2021 .Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A MetaAnalysis. Front Med (Lausanne), 10 : 616380.
Si X,Zhang L,Wang H,Zhang X,Wang M,Han B,Cancer Thorac .2019 .Management of anlotinib-related adverse events in patients with advanced nonsmall cell lung cancer: Experiences in ALTER-0303. , 10(3) : 12977-7714.
Han B,Li K,Wang Q,Zhang L,Shi J,Wang Z .2018 .Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol, 10(11) : 1569-1575.
Lin B,Song X,Yang D,Bai D,Yao Y,Lu N .2018 .Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. , 02 : 77-86.
Daum S,Hagen H,Naismith E,Wolf D,Pircher A .2020 .The Role of Anti-angiogenesis in the Treatment Landscape of Non-Small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition. Front Cell Dev Biol, 10 : 610903.
Chen K,Xu Y,Huang Z,Yu X,Hong W,Li H .2023 .Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial. Cancer Med, 10(19) : 19460-19470.
Zou B,Jiang H,Liu H .2023 .Anlotinib Combined with Anti-PD1 Potentiates Anti-Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming. Adv Therap, 6(11) : 2300141.
Xie C,Wan X,Quan H,Zheng M,Fu L,Li Y .2018 .Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci, 10(4) : 1207-1219.
Abdalla AME,Xiao L,Ullah MW,Yu M,Ouyang C,Yang G .2018 .Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics. , 10(2) : 533-548.
Wu D,Nie J,Dai L,Hu W,Zhang J,Chen X .2019 .Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer, 10(7) : 1759-7714.